Meeting
2019 ASCO Annual Meeting
Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.
Authors
Hans Gelderblom
Leiden University Medical Center, Leiden, Netherlands
Hans Gelderblom , William D. Tap , Emanuela Palmerini , Silvia Stacchiotti , Zev A. Wainberg , Jayesh Desai , John H. Healey , Michiel van de Sande , Nicholas M. Bernthal , Charles Peterfy , Dale Edward Shuster , Qiang Wang , Henry Hsu , Andrew J. Wagner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT01004861 and NCT02371369
Citation
J Clin Oncol 37, 2019 (suppl; abstr 11042)
DOI
10.1200/JCO.2019.37.15_suppl.11042
Abstract #
11042
Poster Bd #
365
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson
Poster
2020 ASCO Virtual Scientific Program
The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.
First Author: Georgina V. Long
Poster
2019 ASCO Annual Meeting
A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.
First Author: Vicky Makker
Poster
2019 ASCO Annual Meeting
Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).
First Author: Hiroaki Akamatsu